Your browser doesn't support javascript.
ROCKY ROAD AHEAD FOR NEW FDA CHIEF CALIFF
Applied Clinical Trials ; 31(3):6, 2022.
Article in English | ProQuest Central | ID: covidwho-20244570
ABSTRACT
Final Senate approval by a historically narrow 50-46 vote came only after the White House and Califf's supporters lobbied hard to gain sufficient support, a success that is very different from Califf's 89-4 approval back in 2016. Pressure to help control the high cost of prescription drugs will continue to drive FDA support for developing complex generic drugs and biosimilars. There is pressure to clarify rules governing e-cigarettes;a need to address serious health problems arising from contaminated food and seafood, including significant volumes of imported products;and the safety of cosmetic products, dietary supplements, sunscreens, and other non-prescription products raise additional complex issues.
Keywords
Search on Google
Collection: Databases of international organizations Database: ProQuest Central Topics: Traditional medicine Language: English Journal: Applied Clinical Trials Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: Databases of international organizations Database: ProQuest Central Topics: Traditional medicine Language: English Journal: Applied Clinical Trials Year: 2022 Document Type: Article